XML 12 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Statement of Profit or Loss and Other Comprehensive Incomestatement of Profit or Loss and Other Comprehensive Income - AUD ($)
 6 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue and other income    
Other income $ 91,921 $ 22,290
Finance Income 160,923 28,667
Expenses    
Research and development expense (4,992,238) (4,282,101)
General and administrative expense (8,558,016) (5,108,573)
Fair value gain/(loss) on financial liabilities 744,920 (1,999,648)
Gain on revaluation of contingent consideration 750,008
Loss before income tax benefit (12,552,490) (10,589,357)
Income tax benefit 135,546
Loss after income tax benefit for the half-year attributable to the owners of Kazia Therapeutics Limited (12,552,490) (10,453,811)
Items that may be reclassified subsequently to profit or loss    
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax (859,893) 174,335
Other comprehensive (loss) / income for the half-year, net of tax (859,893) 174,335
Total comprehensive loss for the half-year attributable to the owners of Kazia Therapeutics Limited $ (13,412,383) $ (10,279,476)
Basic loss per share (in Dollars per share) $ (0.805) $ (2.459)
Diluted loss per share (in Dollars per share) $ (0.805) $ (2.459)